



**Qiyu Li**

**Kontakt**

Qiyu Li

## Publikationen (10)

Huober J, Weder P, Ribi K, Thürlimann B, Thery J, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye A, Müller A, Membrez-Antonioli V, Gerard M, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol* 2023

Beck M, Li Q, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti D, Reuter C, Gomez S, Khanfir K, Aebersold D, Ghadjar P, Schär C, Hayoz S, Papachristofilou A, Sassowsky M, Schär S, Mathier E, Halter M, Zwahlen D, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller A, Putora P, Pra A. Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. *Int J Radiat Oncol Biol Phys* 2022; 113:80-91.

Froesch P, Früh M, Gautschi O, Sessa C, König D, Metaxas Y, Colombo I, Schmid S, Oppliger Leibundgut E, Rusterholz C, Godar G, Li Q, Rothschild S, Mark M, Swiss Group for Clinical Cancer Research (SAKK). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. *Lung Cancer* 2021; 156:91-99.

Brune M, Cogliatti S, Ossenkopppele G, Löwenberg B, Rudolf C, Li Q, Passweg J, Mazzuchelli L, Medinger M, Tzankov A, Fehr M, Grobholz R, Stussi G, Lundberg P, Vela V, Heim D, Manz M, Haralambieva E, Pabst T, Banz Y, Bargetzi M, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. *Ann Hematol* 2021; 100:1169-1179.

Varga Z, Thürlimann B, Klingbiel D, Hawle H, Tille J, Rau T, Perriard U, Jochum W, Li Q, Ruhstaller T. Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. *Sci Rep* 2019; 9:13534.

Schmid S, Jochum W, Klingbiel D, Desbiolles L, Leschka S, Flatz L, Krapf M, Li Q, Diem S, Früh M. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). *Cancer Immunol Immunother* 2018

Gautschi O, Ochsenbein A, Mach N, Biaggi C, Schneider M, Zander T, Froesch P, Peters S, Pless M, Rauch D, Cathomas R, Stahel R, Früh M, Betticher D, Zippelius A, Matter-Walstra K, Li Q, Rothschild S. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. *Clin Lung Cancer* 2016

Varga Z, Cassoly E, Li Q, Öhlschlegel C, Tapia C, Lehr H, Klingbiel D, Thürlimann B, Ruhstaller T. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. *PLoS one* 2015; 10:e0123435.

Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. *Clin Lung Cancer* 2015; 16:358-65.

Hitz F, Ribi K, Li Q, Klingbiel D, Cerny T, Koeberle D. Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer. *Support Care Cancer* 2013; 21:3085-93.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)